Westlake Therapeutics (Hangzhou) Co. Ltd. and affiliated organizations have reported the design and preclinical characterization of novel erythrocytes conjugated to major histocompatibility complex (MHC) class I (MHC-I) protein, being developed for the treatment of cancer.